MoFo Advised Hangzhou DAC Biotechnology on Collaboration and License Agreement with Janssen

Morrison & Foerster LLP advised Hangzhou DAC Biotechnology Co., Ltd. (“DAC Biotechnology”) on its collaboration and license agreement with Janssen Biotech, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the development and commercialization of antibody drug conjugate (ADC) products.

Under the terms of the agreement, DAC Biotechnology will apply its innovative and proprietary ADC platform to Janssen’s proprietary antibodies with the aim to develop novel ADC products against up to five targets.

DAC Biotechnology’s technology concerning payload/linker pairs and conjugation licensed to Janssen is a key component of ADC products. Through the collaboration, DAC Biotechnology will fully leverage its intellectual properties and proprietary ADC platform while Janssen will provide its expertise in proprietary antibodies, clinical development and global commercialization, creating a new approach to progressing novel therapeutic innovations in overseas markets.

The MoFo team advising DAC Biotechnology was led by Shanghai TTG/Corporate Partner Chuan Sun, together with Shanghai TTG associate Sarah Wang.